Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib Safety, Tolerability and Pharmacokinetic Study of Subcutaneously Administered HER-096 in Healthy Volunteer Subjects and Patients With Parkinson's Disease

NCT06659562 is registered in ClinicalTrials.gov with Herantis Pharma Plc. as lead sponsor.

NCT NCT06659562
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06659562 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib Safety, Tolerability and Pharmacokinetic Study of Subcutaneously Administered HER-096 in Healthy Volunteer Subjects and Patients With Parkinson's Disease
Lead sponsor
Herantis Pharma Plc.
Phase
Phase 1
Overall status
Completed
Start date
September 23, 2024
Completion date
August 20, 2025
Enrollment
32 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

parkinson disease, idiopathic